Deadline: 7 November 2019

The European & Developing Countries Clinical Trials Partnership (EDCTP) is seeking proposals to provide funding for clinical trials to be conducted in sub-Saharan Africa which aim to develop new or improved medicinal products (drugs and vaccines) or combinations thereof against pathogens from the WHO priority list that also fall within the scope of the EDCTP2 programme, specifically Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium tuberculosis.

Proposals should include at least one clinical trial (phase I to IV) in sub-Saharan Africa. Proposals should clearly define the activities and mechanisms to be used within the project, including details of any collaboration with public authorities, international organizations or commercial partnerships that will be established in order to achieve the expected impact.

The proposal must include full details of the product development milestones including specific go/no-go criteria for the proposed clinical trial(s) as well as specific plans for the subsequent regulatory approval process.

Projects should include a detailed exploitation plan that describes how project results will be translated into products, policy or practice. The EDCTP Association considers that proposals for actions of between 36- to 60-months duration would allow this specific challenge to be addressed appropriately.

Financial Provisions

• The call budget is EUR 18 million;
• The funding level is 100% of eligible costs.

Expected Impact

Projects funded under this call for proposals should contribute towards national and international plans for containment of antimicrobial resistance.

Eligibility Criteria

A proposal/application will only be considered eligible if:

• its content corresponds, wholly or in part, to the topic/contest description for which it is submitted;
• it complies with the eligibility conditions for participation set out below, depending on the type of action:
  • At least three legal entities. Two of the legal entities shall be established in two different Participating States (European Partner States)** and one of the legal entities must be established in a sub-Saharan African*** country. All three legal entities must be independent of each other.
  • ‘Sole participants’ formed by several legal entities (e.g. European Research Infrastructure Consortia, European Groupings of Territorial Cooperation, central purchasing bodies) are eligible if the above-mentioned minimum conditions are satisfied by the legal entities forming together the sole participant.

**The Participating States (European Partner States) are Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, and the United Kingdom.

***The following sub-Saharan African countries: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo (Democratic People’s Republic), Congo (Republic), Côte d’Ivoire, Djibouti, Eritrea, Ethiopia, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, São Tomé and Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, Togo, Uganda, Zambia, and Zimbabwe.

How to Apply

Applicants can apply via given website.

For more information, please visit http://www.edctp.org/call/new-drugs-and-vaccines-for-priority-pathogens-in-antimicrobial-resistance-2019/